- Home
- DEVS vs UNCY Comparison
DEVS vs UNCY Comparison
Compare DEVS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- UNCY
- Stock Information
- Founded
- DEVS N/A
- UNCY 2016
- Country
- DEVS
- UNCY United States
- Employees
- DEVS N/A
- UNCY N/A
- Industry
- DEVS
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- DEVS
- UNCY Health Care
- Exchange
- DEVS NYSE
- UNCY Nasdaq
- Market Cap
- DEVS 30.1M
- UNCY 31.9M
- IPO Year
- DEVS N/A
- UNCY 2021
- Fundamental
- Price
- DEVS $0.72
- UNCY $0.46
- Analyst Decision
- DEVS
- UNCY Strong Buy
- Analyst Count
- DEVS 0
- UNCY 4
- Target Price
- DEVS N/A
- UNCY $5.50
- AVG Volume (30 Days)
- DEVS N/A
- UNCY 1.9M
- Earning Date
- DEVS N/A
- UNCY 11-13-2024
- Dividend Yield
- DEVS N/A
- UNCY N/A
- EPS Growth
- DEVS N/A
- UNCY N/A
- EPS
- DEVS N/A
- UNCY N/A
- Revenue
- DEVS N/A
- UNCY N/A
- Revenue This Year
- DEVS N/A
- UNCY N/A
- Revenue Next Year
- DEVS N/A
- UNCY N/A
- P/E Ratio
- DEVS N/A
- UNCY N/A
- Revenue Growth
- DEVS N/A
- UNCY N/A
- 52 Week Low
- DEVS N/A
- UNCY $0.20
- 52 Week High
- DEVS N/A
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- UNCY 47.91
- Support Level
- DEVS N/A
- UNCY $0.41
- Resistance Level
- DEVS N/A
- UNCY $0.55
- Average True Range (ATR)
- DEVS 0.00
- UNCY 0.06
- MACD
- DEVS 0.00
- UNCY -0.01
- Stochastic Oscillator
- DEVS 0.00
- UNCY 20.97
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.